Grade and prognosis in localized primary angiosarcoma

Manjari Pandey, Gregory R. Sutton, Smith Giri, Michael Martin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background Primary angiosarcoma of the breast (PAOB) is rare and institutional series have provided conflicting data on the effect of grade on prognosis. Patients and Methods Using a case listing session of Surveillance, Epidemiology, and End Results (SEER) 18 (1973-2010) we examined outcomes for patients with PAOB. Analyses were conducted with SEER∗Stat 8.1.2, Microsoft Excel 2007, and GraphPad Prism 6. Comparisons were made using the Fisher exact test and log rank test (Mantel-Cox); P values were 2-sided. Results Two hundred twenty-six women with PAOB were identified; median age was 49 (range, 15-107) years and 82% (185) were white. Seventy-two percent (162) had localized disease, 15% (34) regional disease, 7% (16) distant disease, and 6% (14) had unknown staging. Fourteen percent (32) had Grade 1, 24% (55) Grade 2, 30% (68) Grade 3 disease, and grade was unknown in 32% (72) of patients. Median overall survival (OS) for patients with localized, regional, and distant disease was 172, 24, and 16 months, respectively (P <.001). Median OS for patients with localized Grade 1 and 2 disease was not reached versus 36 months for Grade 3 disease (P <.001); 3-year OS was 89% (78) versus 47% (32). There was a strong trend for patients with Grade 3 disease to undergo mastectomy (44%, n = 30 vs. 23%, n = 20; P =.070) and 24% (55) of all patients received radiation. Radiation did not improve survival for localized Grade 1 and 2 disease (P =.676), or Grade 3 disease (P =.589); surgery and grade subgroups were too small for meaningful comparisons regarding radiation. Conclusion Histologic grade is a significant predictor of survival for patients with localized PAOB. Regardless of grade, adjuvant radiation did not confer a survival benefit for patients with localized disease.

Original languageEnglish (US)
Pages (from-to)266-269
Number of pages4
JournalClinical Breast Cancer
Volume15
Issue number4
DOIs
StatePublished - Jan 1 2015

Fingerprint

Hemangiosarcoma
Survival
Radiation
Mastectomy
Epidemiology

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Grade and prognosis in localized primary angiosarcoma. / Pandey, Manjari; Sutton, Gregory R.; Giri, Smith; Martin, Michael.

In: Clinical Breast Cancer, Vol. 15, No. 4, 01.01.2015, p. 266-269.

Research output: Contribution to journalArticle

Pandey, Manjari ; Sutton, Gregory R. ; Giri, Smith ; Martin, Michael. / Grade and prognosis in localized primary angiosarcoma. In: Clinical Breast Cancer. 2015 ; Vol. 15, No. 4. pp. 266-269.
@article{399c7996151b482aa9e6d0a168361991,
title = "Grade and prognosis in localized primary angiosarcoma",
abstract = "Background Primary angiosarcoma of the breast (PAOB) is rare and institutional series have provided conflicting data on the effect of grade on prognosis. Patients and Methods Using a case listing session of Surveillance, Epidemiology, and End Results (SEER) 18 (1973-2010) we examined outcomes for patients with PAOB. Analyses were conducted with SEER∗Stat 8.1.2, Microsoft Excel 2007, and GraphPad Prism 6. Comparisons were made using the Fisher exact test and log rank test (Mantel-Cox); P values were 2-sided. Results Two hundred twenty-six women with PAOB were identified; median age was 49 (range, 15-107) years and 82{\%} (185) were white. Seventy-two percent (162) had localized disease, 15{\%} (34) regional disease, 7{\%} (16) distant disease, and 6{\%} (14) had unknown staging. Fourteen percent (32) had Grade 1, 24{\%} (55) Grade 2, 30{\%} (68) Grade 3 disease, and grade was unknown in 32{\%} (72) of patients. Median overall survival (OS) for patients with localized, regional, and distant disease was 172, 24, and 16 months, respectively (P <.001). Median OS for patients with localized Grade 1 and 2 disease was not reached versus 36 months for Grade 3 disease (P <.001); 3-year OS was 89{\%} (78) versus 47{\%} (32). There was a strong trend for patients with Grade 3 disease to undergo mastectomy (44{\%}, n = 30 vs. 23{\%}, n = 20; P =.070) and 24{\%} (55) of all patients received radiation. Radiation did not improve survival for localized Grade 1 and 2 disease (P =.676), or Grade 3 disease (P =.589); surgery and grade subgroups were too small for meaningful comparisons regarding radiation. Conclusion Histologic grade is a significant predictor of survival for patients with localized PAOB. Regardless of grade, adjuvant radiation did not confer a survival benefit for patients with localized disease.",
author = "Manjari Pandey and Sutton, {Gregory R.} and Smith Giri and Michael Martin",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.clbc.2014.12.009",
language = "English (US)",
volume = "15",
pages = "266--269",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Grade and prognosis in localized primary angiosarcoma

AU - Pandey, Manjari

AU - Sutton, Gregory R.

AU - Giri, Smith

AU - Martin, Michael

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background Primary angiosarcoma of the breast (PAOB) is rare and institutional series have provided conflicting data on the effect of grade on prognosis. Patients and Methods Using a case listing session of Surveillance, Epidemiology, and End Results (SEER) 18 (1973-2010) we examined outcomes for patients with PAOB. Analyses were conducted with SEER∗Stat 8.1.2, Microsoft Excel 2007, and GraphPad Prism 6. Comparisons were made using the Fisher exact test and log rank test (Mantel-Cox); P values were 2-sided. Results Two hundred twenty-six women with PAOB were identified; median age was 49 (range, 15-107) years and 82% (185) were white. Seventy-two percent (162) had localized disease, 15% (34) regional disease, 7% (16) distant disease, and 6% (14) had unknown staging. Fourteen percent (32) had Grade 1, 24% (55) Grade 2, 30% (68) Grade 3 disease, and grade was unknown in 32% (72) of patients. Median overall survival (OS) for patients with localized, regional, and distant disease was 172, 24, and 16 months, respectively (P <.001). Median OS for patients with localized Grade 1 and 2 disease was not reached versus 36 months for Grade 3 disease (P <.001); 3-year OS was 89% (78) versus 47% (32). There was a strong trend for patients with Grade 3 disease to undergo mastectomy (44%, n = 30 vs. 23%, n = 20; P =.070) and 24% (55) of all patients received radiation. Radiation did not improve survival for localized Grade 1 and 2 disease (P =.676), or Grade 3 disease (P =.589); surgery and grade subgroups were too small for meaningful comparisons regarding radiation. Conclusion Histologic grade is a significant predictor of survival for patients with localized PAOB. Regardless of grade, adjuvant radiation did not confer a survival benefit for patients with localized disease.

AB - Background Primary angiosarcoma of the breast (PAOB) is rare and institutional series have provided conflicting data on the effect of grade on prognosis. Patients and Methods Using a case listing session of Surveillance, Epidemiology, and End Results (SEER) 18 (1973-2010) we examined outcomes for patients with PAOB. Analyses were conducted with SEER∗Stat 8.1.2, Microsoft Excel 2007, and GraphPad Prism 6. Comparisons were made using the Fisher exact test and log rank test (Mantel-Cox); P values were 2-sided. Results Two hundred twenty-six women with PAOB were identified; median age was 49 (range, 15-107) years and 82% (185) were white. Seventy-two percent (162) had localized disease, 15% (34) regional disease, 7% (16) distant disease, and 6% (14) had unknown staging. Fourteen percent (32) had Grade 1, 24% (55) Grade 2, 30% (68) Grade 3 disease, and grade was unknown in 32% (72) of patients. Median overall survival (OS) for patients with localized, regional, and distant disease was 172, 24, and 16 months, respectively (P <.001). Median OS for patients with localized Grade 1 and 2 disease was not reached versus 36 months for Grade 3 disease (P <.001); 3-year OS was 89% (78) versus 47% (32). There was a strong trend for patients with Grade 3 disease to undergo mastectomy (44%, n = 30 vs. 23%, n = 20; P =.070) and 24% (55) of all patients received radiation. Radiation did not improve survival for localized Grade 1 and 2 disease (P =.676), or Grade 3 disease (P =.589); surgery and grade subgroups were too small for meaningful comparisons regarding radiation. Conclusion Histologic grade is a significant predictor of survival for patients with localized PAOB. Regardless of grade, adjuvant radiation did not confer a survival benefit for patients with localized disease.

UR - http://www.scopus.com/inward/record.url?scp=84946496924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946496924&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2014.12.009

DO - 10.1016/j.clbc.2014.12.009

M3 - Article

VL - 15

SP - 266

EP - 269

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 4

ER -